The longevity biotech and epigenetic reprogramming market size has grown rapidly in recent years. It will grow from $23.93 billion in 2025 to $27.11 billion in 2026 at a compound annual growth rate (CAGR) of 13.3%. The growth in the historic period can be attributed to growth in aging population demographics, increasing investment in regenerative medicine research, expansion of genomic and molecular biology studies, rising prevalence of age-related chronic diseases, growth in venture capital funding for longevity research.
The longevity biotech and epigenetic reprogramming market size is expected to see rapid growth in the next few years. It will grow to $44.05 billion in 2030 at a compound annual growth rate (CAGR) of 12.9%. The growth in the forecast period can be attributed to increasing development of personalized anti-aging therapies, rising demand for preventive healthcare solutions, expansion of gene editing technologies, increasing clinical trials for longevity therapeutics, growth in strategic partnerships across biotechnology ecosystems. Major trends in the forecast period include increasing development of partial epigenetic reprogramming therapies, rising focus on senolytic and senomorphic therapeutic approaches, growing investment in stem cell based regenerative interventions, increasing research activities in age-related disease targeting therapies, rising adoption of metabolic intervention strategies for healthy aging.
The rising prevalence of age-related chronic diseases is expected to propel the growth of the longevity biotech and epigenetic reprogramming market going forward. Age-related chronic diseases are persistent health conditions, such as heart disease, diabetes, arthritis, and dementia, that emerge or worsen with advancing age due to the gradual deterioration of physiological functions. The increasing incidence of age-related chronic diseases is primarily driven by the cumulative effects of unhealthy lifestyle habits over time, which progressively impair bodily systems and elevate disease risk as individuals age. Longevity biotech and epigenetic reprogramming can help address age-related chronic diseases by altering gene expression patterns to slow down or partially reverse cellular aging, thereby enhancing tissue function and limiting disease progression. For instance, in December 2025, according to the Australian Institute of Health and Welfare, an Australia-based government agency, around 425,000 Australians were living with dementia in 2024, and this figure is projected to rise 2.5-fold to more than 1.1 million by 2065, including approximately 662,000 women and 390,000 men. Therefore, the rising prevalence of age-related chronic diseases is driving the growth of the longevity biotech and epigenetic reprogramming market.
The increasing healthcare expenditure is expected to propel the growth of the longevity biotech and epigenetic reprogramming market going forward. Healthcare expenditure refers to the total amount spent by governments, organizations, and individuals on medical services, healthcare products, and activities intended to maintain or improve health outcomes. Healthcare spending is rising due to advancements in medical technology, as the adoption of innovative diagnostic tools, robotic-assisted surgeries, and advanced treatment procedures enhances patient care while increasing the overall cost of healthcare delivery. Growing healthcare expenditure supports longevity biotech and epigenetic reprogramming by providing greater funding for advanced research, clinical trials, and the adoption of high-cost regenerative therapies designed to slow, prevent, or reverse biological aging. For instance, in April 2025, according to the Office for National Statistics, a UK-based independent producer of official statistics, healthcare spending in the UK reached approximately $370.71 billion (£317 billion) in 2024, representing a 6.5% nominal increase compared with 2023. Therefore, the increasing healthcare expenditure is driving the growth of the longevity biotech and epigenetic reprogramming market.
Major companies operating in the longevity biotech and epigenetic reprogramming market are focusing on developing innovative solutions, such as investigational new drug (IND) applications, to advance first-in-human clinical trials of epigenetic reprogramming therapies aimed at reversing cellular aging and treating age-related chronic diseases. An investigational new drug (IND) application is a regulatory submission that enables a company or researcher to initiate human clinical testing of a new drug by providing evidence of preliminary safety, laboratory findings, and clinical trial protocols to regulatory authorities before trials commence. For instance, in January 2026, Life Biosciences, a US-based biotechnology company, received U.S. FDA clearance for its investigational new drug (IND) application for ER-100, the first cellular rejuvenation therapy based on partial epigenetic reprogramming to enter human clinical trials. The therapy is being assessed in a Phase 1 clinical trial for optic neuropathies, including glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION), using controlled expression of Yamanaka factors (OSK) to rejuvenate aging retinal cells. This milestone marks a significant advancement in the translation of epigenetic reprogramming technologies into human therapeutic applications.
Major companies operating in the longevity biotech and epigenetic reprogramming market are Altos Labs Inc.; Retro Biosciences Inc.; NewLimit Inc.; Life Biosciences Inc.; Calico Life Sciences LLC; BioAge Labs Inc.; Juvenescence; Unity Biotechnology; Turn Biotechnologies Inc.; Moonwalk Biosciences; Rejuvenate Bio Inc.; Shift Bioscience Ltd; AgeX Therapeutics Inc.; YouthBio Therapeutics.
North America was the largest region in the longevity biotechnology and epigenetic reprogramming market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the longevity biotech and epigenetic reprogramming market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the longevity biotech and epigenetic reprogramming market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The longevity biotechnology and epigenetic reprogramming market consists of revenues earned by entities by providing services such as epigenetic age testing and biological age assessment, cellular rejuvenation therapy development, and gene therapy-based anti-aging solutions. The market value includes the value of related goods sold by the service provider or included within the service offering. The longevity biotechnology and epigenetic reprogramming market also includes sales of cellular reprogramming kits, epigenetic biomarker testing kits, and senolytic drugs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
The longevity biotech and epigenetic reprogramming market research report is one of a series of new reports that provides longevity biotech and epigenetic reprogramming market statistics, including longevity biotech and epigenetic reprogramming industry global market size, regional shares, competitors with a longevity biotech and epigenetic reprogramming market share, detailed longevity biotech and epigenetic reprogramming market segments, market trends and opportunities, and any further data you may need to thrive in the longevity biotech and epigenetic reprogramming industry. This longevity biotech and epigenetic reprogramming market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
This product will be delivered within 1-3 business days.
The longevity biotech and epigenetic reprogramming market size is expected to see rapid growth in the next few years. It will grow to $44.05 billion in 2030 at a compound annual growth rate (CAGR) of 12.9%. The growth in the forecast period can be attributed to increasing development of personalized anti-aging therapies, rising demand for preventive healthcare solutions, expansion of gene editing technologies, increasing clinical trials for longevity therapeutics, growth in strategic partnerships across biotechnology ecosystems. Major trends in the forecast period include increasing development of partial epigenetic reprogramming therapies, rising focus on senolytic and senomorphic therapeutic approaches, growing investment in stem cell based regenerative interventions, increasing research activities in age-related disease targeting therapies, rising adoption of metabolic intervention strategies for healthy aging.
The rising prevalence of age-related chronic diseases is expected to propel the growth of the longevity biotech and epigenetic reprogramming market going forward. Age-related chronic diseases are persistent health conditions, such as heart disease, diabetes, arthritis, and dementia, that emerge or worsen with advancing age due to the gradual deterioration of physiological functions. The increasing incidence of age-related chronic diseases is primarily driven by the cumulative effects of unhealthy lifestyle habits over time, which progressively impair bodily systems and elevate disease risk as individuals age. Longevity biotech and epigenetic reprogramming can help address age-related chronic diseases by altering gene expression patterns to slow down or partially reverse cellular aging, thereby enhancing tissue function and limiting disease progression. For instance, in December 2025, according to the Australian Institute of Health and Welfare, an Australia-based government agency, around 425,000 Australians were living with dementia in 2024, and this figure is projected to rise 2.5-fold to more than 1.1 million by 2065, including approximately 662,000 women and 390,000 men. Therefore, the rising prevalence of age-related chronic diseases is driving the growth of the longevity biotech and epigenetic reprogramming market.
The increasing healthcare expenditure is expected to propel the growth of the longevity biotech and epigenetic reprogramming market going forward. Healthcare expenditure refers to the total amount spent by governments, organizations, and individuals on medical services, healthcare products, and activities intended to maintain or improve health outcomes. Healthcare spending is rising due to advancements in medical technology, as the adoption of innovative diagnostic tools, robotic-assisted surgeries, and advanced treatment procedures enhances patient care while increasing the overall cost of healthcare delivery. Growing healthcare expenditure supports longevity biotech and epigenetic reprogramming by providing greater funding for advanced research, clinical trials, and the adoption of high-cost regenerative therapies designed to slow, prevent, or reverse biological aging. For instance, in April 2025, according to the Office for National Statistics, a UK-based independent producer of official statistics, healthcare spending in the UK reached approximately $370.71 billion (£317 billion) in 2024, representing a 6.5% nominal increase compared with 2023. Therefore, the increasing healthcare expenditure is driving the growth of the longevity biotech and epigenetic reprogramming market.
Major companies operating in the longevity biotech and epigenetic reprogramming market are focusing on developing innovative solutions, such as investigational new drug (IND) applications, to advance first-in-human clinical trials of epigenetic reprogramming therapies aimed at reversing cellular aging and treating age-related chronic diseases. An investigational new drug (IND) application is a regulatory submission that enables a company or researcher to initiate human clinical testing of a new drug by providing evidence of preliminary safety, laboratory findings, and clinical trial protocols to regulatory authorities before trials commence. For instance, in January 2026, Life Biosciences, a US-based biotechnology company, received U.S. FDA clearance for its investigational new drug (IND) application for ER-100, the first cellular rejuvenation therapy based on partial epigenetic reprogramming to enter human clinical trials. The therapy is being assessed in a Phase 1 clinical trial for optic neuropathies, including glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION), using controlled expression of Yamanaka factors (OSK) to rejuvenate aging retinal cells. This milestone marks a significant advancement in the translation of epigenetic reprogramming technologies into human therapeutic applications.
Major companies operating in the longevity biotech and epigenetic reprogramming market are Altos Labs Inc.; Retro Biosciences Inc.; NewLimit Inc.; Life Biosciences Inc.; Calico Life Sciences LLC; BioAge Labs Inc.; Juvenescence; Unity Biotechnology; Turn Biotechnologies Inc.; Moonwalk Biosciences; Rejuvenate Bio Inc.; Shift Bioscience Ltd; AgeX Therapeutics Inc.; YouthBio Therapeutics.
North America was the largest region in the longevity biotechnology and epigenetic reprogramming market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the longevity biotech and epigenetic reprogramming market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the longevity biotech and epigenetic reprogramming market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The longevity biotechnology and epigenetic reprogramming market consists of revenues earned by entities by providing services such as epigenetic age testing and biological age assessment, cellular rejuvenation therapy development, and gene therapy-based anti-aging solutions. The market value includes the value of related goods sold by the service provider or included within the service offering. The longevity biotechnology and epigenetic reprogramming market also includes sales of cellular reprogramming kits, epigenetic biomarker testing kits, and senolytic drugs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
The longevity biotech and epigenetic reprogramming market research report is one of a series of new reports that provides longevity biotech and epigenetic reprogramming market statistics, including longevity biotech and epigenetic reprogramming industry global market size, regional shares, competitors with a longevity biotech and epigenetic reprogramming market share, detailed longevity biotech and epigenetic reprogramming market segments, market trends and opportunities, and any further data you may need to thrive in the longevity biotech and epigenetic reprogramming industry. This longevity biotech and epigenetic reprogramming market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Longevity Biotech And Epigenetic Reprogramming Market Characteristics
3. Longevity Biotech And Epigenetic Reprogramming Market Supply Chain Analysis
4. Global Longevity Biotech And Epigenetic Reprogramming Market Trends And Strategies
5. Longevity Biotech And Epigenetic Reprogramming Market Analysis Of End Use Industries
7. Global Longevity Biotech And Epigenetic Reprogramming Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis
8. Global Longevity Biotech And Epigenetic Reprogramming Total Addressable Market (TAM) Analysis for the Market
9. Longevity Biotech And Epigenetic Reprogramming Market Segmentation
10. Longevity Biotech And Epigenetic Reprogramming Market Regional And Country Analysis
11. Asia-Pacific Longevity Biotech And Epigenetic Reprogramming Market
12. China Longevity Biotech And Epigenetic Reprogramming Market
13. India Longevity Biotech And Epigenetic Reprogramming Market
14. Japan Longevity Biotech And Epigenetic Reprogramming Market
15. Australia Longevity Biotech And Epigenetic Reprogramming Market
16. Indonesia Longevity Biotech And Epigenetic Reprogramming Market
17. South Korea Longevity Biotech And Epigenetic Reprogramming Market
18. Taiwan Longevity Biotech And Epigenetic Reprogramming Market
19. South East Asia Longevity Biotech And Epigenetic Reprogramming Market
20. Western Europe Longevity Biotech And Epigenetic Reprogramming Market
21. UK Longevity Biotech And Epigenetic Reprogramming Market
22. Germany Longevity Biotech And Epigenetic Reprogramming Market
23. France Longevity Biotech And Epigenetic Reprogramming Market
24. Italy Longevity Biotech And Epigenetic Reprogramming Market
25. Spain Longevity Biotech And Epigenetic Reprogramming Market
26. Eastern Europe Longevity Biotech And Epigenetic Reprogramming Market
27. Russia Longevity Biotech And Epigenetic Reprogramming Market
28. North America Longevity Biotech And Epigenetic Reprogramming Market
29. USA Longevity Biotech And Epigenetic Reprogramming Market
30. Canada Longevity Biotech And Epigenetic Reprogramming Market
31. South America Longevity Biotech And Epigenetic Reprogramming Market
32. Brazil Longevity Biotech And Epigenetic Reprogramming Market
33. Middle East Longevity Biotech And Epigenetic Reprogramming Market
34. Africa Longevity Biotech And Epigenetic Reprogramming Market
36. Longevity Biotech And Epigenetic Reprogramming Market Competitive Landscape And Company Profiles
37. Longevity Biotech And Epigenetic Reprogramming Market Other Major And Innovative Companies
41. Longevity Biotech And Epigenetic Reprogramming Market High Potential Countries, Segments and Strategies
42. Appendix
Executive Summary
Longevity Biotech And Epigenetic Reprogramming Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses longevity biotech and epigenetic reprogramming market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for longevity biotech and epigenetic reprogramming? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The longevity biotech and epigenetic reprogramming market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Technology Platform: Partial Epigenetic Reprogramming; Senolytics And Senomorphics; Gene Therapy; Stem Cell Therapy; Metabolic Intervention2) By Therapeutic Focus: Age Related Ocular Disease; Cardiovascular Aging; Neurodegeneration; Musculoskeletal Decline; Metabolic Aging
3) By Delivery Method: In Vivo Therapies; Ex Vivo Therapies; Small Molecule Therapies; Biologic Therapies; Gene Editing Based Therapies; Cell Based Therapies; Other Delivery Methods
4) By Funding Source: Venture Capital; Government (Advanced Research Projects Agency For Health); Philanthropic; Public Markets
5) By End User: Biotechnology Companies; Pharmaceutical Companies; Research Institutes; Academic And Scientific Organizations; Hospitals And Clinics; Contract Research Organizations; Other End Users
Subsegments:
1) By Partial Epigenetic Reprogramming: Transient Yamanaka Factor Delivery; Small Molecule Epigenetic Modulators; Messenger Ribonucleic Acid Based Reprogramming; Protein Based Reprogramming; Viral Vector Based Delivery2) By Senolytics And Senomorphics: Apoptosis Inducing Senolytic Agents; Immune Modulating Senomorphics; Natural Compound Based Senolytic Agents; Targeted Antibody Based Senolytic Therapies; Combination Senescence Targeted Therapies
3) By Gene Therapy: Adeno Associated Virus Based Gene Delivery Systems; Lentiviral Gene Therapy Platforms; Clustered Regularly Interspaced Short Palindromic Repeats Gene Editing Systems; Messenger Ribonucleic Acid Gene Regulation Therapies; Ribonucleic Acid Interference Gene Silencing Approaches
4) By Stem Cell Therapy: Mesenchymal Stem Cell Based Therapy; Induced Pluripotent Stem Cell Based Therapy; Hematopoietic Stem Cell Based Therapy; Exosome Mediated Stem Cell Therapy; Allogeneic And Autologous Stem Cell Based Therapy
5) By Metabolic Intervention: Caloric Restriction Mimetic Compounds; Mitochondrial Function Enhancement Therapies; Nicotinamide Adenine Dinucleotide Boosting Therapies; Adenosine Monophosphate Activated Protein Kinase Activation Therapies; Hormonal And Insulin Sensitization Therapies
Companies Mentioned: Altos Labs Inc.; Retro Biosciences Inc.; NewLimit Inc.; Life Biosciences Inc.; Calico Life Sciences LLC; BioAge Labs Inc.; Juvenescence; Unity Biotechnology; Turn Biotechnologies Inc.; Moonwalk Biosciences; Rejuvenate Bio Inc.; Shift Bioscience Ltd; AgeX Therapeutics Inc.; YouthBio Therapeutics
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
- Altos Labs Inc.
- Retro Biosciences Inc.
- NewLimit Inc.
- Life Biosciences Inc.
- Calico Life Sciences LLC
- BioAge Labs Inc.
- Juvenescence
- Unity Biotechnology
- Turn Biotechnologies Inc.
- Moonwalk Biosciences
- Rejuvenate Bio Inc.
- Shift Bioscience Ltd
- AgeX Therapeutics Inc.
- YouthBio Therapeutics
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | August 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 27.11 Billion |
| Forecasted Market Value ( USD | $ 44.05 Billion |
| Compound Annual Growth Rate | 12.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 14 |
